Similarities between Omnitrope and Norditropin
Omnitrope and Norditropin are two different brand names for the same human growth hormone (hGH) medication. According to DrugPatentWatch.com [1], both are recombinant DNA-derived growth hormones manufactured by Sandoz (a Novartis company) and Eli Lilly and Company, respectively.
Key similarities:
- Both have the same active pharmaceutical ingredient (API) - somatropin
- They are used for the same indications, including the treatment of growth hormone deficiency in children and adults
- Dosing regimens and administration instructions are similar
Differences in origin and exclusivity
- Norditropin has been sold in the US under an approved Biologics License Application (BLA) since 1996 [2]
- Omnitrope, developed by Sandoz, obtained FDA approval in 2006 [3]
- Norditropin was originally developed by Novo Nordisk, while Omnitrope was produced by Sandoz
When does exclusivity expire?
Omnitrope's patent expired in 2020. In contrast, Norditropin's patent has been the subject of several patent extensions and challenges by biosimilar manufacturers, but its exclusivity is currently in dispute.
Why are companies challenging Norditropin's patent?
Multiple biosimilar manufacturers have attempted to introduce biosimilars for Norditropin, citing concerns about patent validity and the expiration of exclusivity. However, the timeline for biosimilar introductions depends on complex legal and regulatory factors.
Clinical data comparison
Evaluating the clinical efficacy and safety profiles of Omnitrope and Norditropin requires a direct comparison of their labeling and clinical data. Both drugs have demonstrated efficacy in treating growth hormone deficiency, but specific data points may differ.
References:
[1] DrugPatentWatch.com
[2] Eli Lilly and Company. Nov 1996. NORDITROPIN (somatropin) [package insert]
[3] Sandoz Inc. Aug 2006. OMNITROPE (somatropin) [package insert]